维多利祖马布诱导的间歇性肺病:一种延迟发作的肺毒性病例
Tania Lasrado1, Qais Akasheh1, Shabnam Enam1
1Respiratory Medicine, East Suffolk and North Essex NHS Foundation Trust, Ipswich, GBR.
Cureus
|December 15, 2025
概括
维多利祖马布是一种治疗炎症性肠病 (IBD) 的药物,很少会导致肺部问题. 停止服用该药物导致一名疑似患有vedolizumab诱导的间歇性肺病 (ILD) 的患者显著改善.
科学领域:
- 胃肠病学 胃肠病学
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 维多利祖马布是一种适度至严重的炎症性肠病 (IBD) 的生物疗法.
- 肺毒性,包括间歇性肺病 (ILD),是一种与vedolizumab相关的罕见不良事件.
- 早期识别和治疗药物诱导的ILD至关重要.
研究的目的:
- 在患有性结肠炎 (UC) 的患者中报告可能由vedolizumab诱导的间歇性肺病 (ILD).
- 要突出诊断挑战和临床过程的Vedolizumab诱导的ILD.
- 强调在新出现呼吸道症状的生物治疗患者中考虑药物诱导的ILD的重要性.
主要方法:
- 一个46岁的女性患有性结肠炎 (UC),接受了视多利祖马布治疗的病例报告.
- 临床评估,成像 (放射/CT),排除肺部疾病的其他原因.
- 对韦多利祖马布停药和皮质类固醇治疗的反应评估.
主要成果:
- 患者出现了渐进的呼吸不全和咳,最初用皮质类固醇治疗,但没有改善.
- 图像检测显示了扩散的心球节点,暗示过敏性肺炎.
- 暂停vedolizumab导致显著的临床,功能和放射性改善,支持诊断vedolizumab诱导的ILD.
结论:
- 维多利祖马布诱导的ILD是一种罕见但严重的潜在不良反应,应考虑在接受这种治疗的IBD患者中出现呼吸系统症状.
- 由于非特定的临床和放射学发现,诊断可能具有挑战性.
- 早期识别和戒毒对于有利的结果和预防长期肺损伤至关重要.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
676
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
676
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.1K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.1K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
01:26COPD: Management Using Bronchodilators and Corticosteroids
700
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
700
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459